Hitt Sharma

Dr. Hitt Sharma


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in The Lancet Oncology
Verified
Journal Article
Closed access
HSHitt Sharma
Hitt Sharma
SPSameer Parekh
Sameer Parekh
PPPramod Pujari
Pramod Pujari
SSSunil Shewale
Sunil Shewale
SDShivani Desai
Shivani Desai
USUmesh Shaligram
Umesh Shaligram

8 November 2011 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
HSHitt Sharma
Hitt Sharma
VPVasant S Padbidri
Vasant S Padbidri
SKSubhash V Kapre
Subhash V Kapre
SJSuresh S Jadhav
Suresh S Jadhav
RDRajeev M Dhere
Rajeev M Dhere
GNGajanan S Namjoshi
Gajanan S Namjoshi
Introduction: Serologic surveys conducted in different countries indicate that rubella is a worldwide infection. Several such sero surveys conducted in India have also confirmed that 6-47% of women are susceptible to rubella infection. The current study was conducted on 1,329 female adolescents in 12 districts of Maharashtra, India, to assess their serological status in terms of rubella exposure. Methodology: After enrollment, a pre-vaccination blood sample was collected from the participants followed by rubella vaccination (R-vac). Adverse events were monitored for the next 6-8 weeks, at which time a post-vaccination sample was collected. Results: Pre-vaccination rubella immunity was higher in the urban (80.2%) population compared to the rural (73.1%) population. Following R-vac vaccination, out of 1,159 participants who completed the study, all (100%) in the urban and 99.5% of participants in the rural area developed antibodies against rubella. Conclusion: Substantial numbers of women reach childbearing age without immunity against rubella and thus are at a risk of passing the infection to their fetuses, who can then develop subsequent congenital defects leading to congenital rubella syndrome (CRS). An immunization policy recommending vaccination with rubella or rubella containing vaccine is highly desirable to prevent rubella and CRS.

16 March 2011 in Vaccine
Verified
Journal Article
Closed access
HSHitt Sharma
Hitt Sharma
SYSangita Yadav
Sangita Yadav
SLSanjay Lalwani
Sanjay Lalwani
VGVijay Gupta
Vijay Gupta
SKSubhash Kapre
Subhash Kapre
SPSonali Palkar
Sonali Palkar

1 April 2011 in Human Vaccines
Verified
Journal Article
Closed access
HSHitt Sharma
Hitt Sharma
SYSangita Yadav
Sangita Yadav
SLSanjay K. Lalwani
Sanjay K. Lalwani
SKSubhash V. Kapre
Subhash V. Kapre
SJSuresh S. Jadhav
Suresh S. Jadhav
VVVikas Verma
Vikas Verma
Objective: An open label, controlled clinical study was conducted in Indian infants aged 6-14 weeks to compare the immunogenicity and safety of a reconstituted pentavalent vaccine (DTwP-HBV+Hib) of...

1 January 2010 in Indian Journal of Community Medicine
Verified
Journal Article
Open access
PDF file
HSHitt Sharma
Hitt Sharma
SCSunil Chowdhari
Sunil Chowdhari
TRTilak Raj Raina
Tilak Raj Raina
SBSubodh Bhardwaj
Subodh Bhardwaj
GNGajanan Namjoshi
Gajanan Namjoshi
SPSameer Parekh
Sameer Parekh
Background: Rubella vaccination is not yet included in National Immunization Schedule in India. Serosurvey is frequently used to assess epidemiologic pattern of Rubella in a community. Serosurveys in different parts of India have found that 6-47% of women are susceptible for Rubella infection. The present serosurveillance was conducted in Jammu, India, in two public schools. Objective: To determine serological status of Rubella antibodies of school girls and assessment of immunogenicity and reactogenicity of Rubella immunization in seronegative girls. Materials and Methods: The current study was conducted to determine Rubella serostatus in peripubertal schoolgirls aged 11-18 years and also to assess immunogenicity and safety of Rubella vaccine (R-Vac) of Serum Institute of India Ltd., Pune, in seronegative girls. For screening, pre-vaccination serum Rubella IgG antibodies were determined and to assess immunogenicity of the vaccine, post-vaccination IgG antibodies were compared with pre-vaccination levels. Safety assessment was done for a period of 8 weeks, post-vaccination. Results: A total of 90 (32.7%) seronegative girls were vaccinated. All girls (100%) became seropositive, post-vaccination. Clinically relevant and statistically significant increase in anti-Rubella IgG titres was observed. The adverse events were mild and self-limiting. Conclusions: R-Vac vaccine used in the study demonstrated an excellent safety and immunogenicity profile.

1 January 2013 in Vaccine
Verified
Journal Article
Closed access
HSHitt Sharma
Hitt Sharma
SYSangeeta Yadav
Sangeeta Yadav
SLSanjay Lalwani
Sanjay Lalwani
SKSubhash Kapre
Subhash Kapre
SJSuresh Jadhav
Suresh Jadhav
SSSunil Shewale
Sunil Shewale